These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

124 related items for PubMed ID: 7691696

  • 21. ACTG 175 and Delta.
    Torres G.
    GMHC Treat Issues; 1995 Oct; 9(10):2-3. PubMed ID: 11362915
    [Abstract] [Full Text] [Related]

  • 22. [AIDS. Combination therapy is more favorable].
    Fortschr Med; 1988 Sep 30; 106(28):57. PubMed ID: 3069665
    [No Abstract] [Full Text] [Related]

  • 23. Resisting the temptation.
    Lancet; 1993 Aug 21; 342(8869):448. PubMed ID: 7688842
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Research study of combination AIDS therapies underway.
    AIDS Patient Care STDS; 1996 Apr 21; 10(2):132. PubMed ID: 11361697
    [No Abstract] [Full Text] [Related]

  • 28. [Nevirapine: a new principle of action against HIV].
    Dtsch Med Wochenschr; 1996 Dec 06; 121(49):A48-9. PubMed ID: 8998915
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Antiretroviral treatment: state of the art and future directions.
    Lange JM, Cooper DA, Danner SA.
    AIDS; 1991 Dec 06; 5 Suppl 2():S181-8. PubMed ID: 1726955
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. '96-'97 new drugs and the nominees for 1997 are...
    Notes Undergr; 1997 Dec 06; (No 35):suppl 1-2. PubMed ID: 11364566
    [Abstract] [Full Text] [Related]

  • 33. Protease inhibitors and prevention of cross resistance.
    Levin J.
    AIDS Treat News; 1995 Oct 06; (no 232):1-3. PubMed ID: 11362875
    [Abstract] [Full Text] [Related]

  • 34. FDA triple header. Food and Drug Administration.
    Smart T.
    GMHC Treat Issues; 1995 Nov 06; 9(11):1-3. PubMed ID: 11362986
    [Abstract] [Full Text] [Related]

  • 35. New trials reach same conclusion: two drugs are better than AZT alone.
    AIDS Alert; 1995 Nov 06; 10(11):133-6. PubMed ID: 11362921
    [Abstract] [Full Text] [Related]

  • 36. Zidovudine plus didanosine in primary HIV-1 infection.
    Perrin L, Yerly S, Charvier A, Figueras G, Schockmel GA, Hirschel B.
    Antivir Ther; 1997 Jan 06; 2(1):5-11. PubMed ID: 11322267
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. [Effect of treatment with nucleoside analogues in subjects with primary genotypic resistance to zidovudine].
    Leal M, Caruz A, Rey C, Lissen E.
    Med Clin (Barc); 1996 Nov 30; 107(19):755. PubMed ID: 9082095
    [No Abstract] [Full Text] [Related]

  • 39. Delavirdine data: skewed or skewered?
    Mascolini M.
    J Int Assoc Physicians AIDS Care; 1997 Feb 30; 3(2):42-6. PubMed ID: 11364099
    [Abstract] [Full Text] [Related]

  • 40. AIDS therapy with two, three or four agent combinations, applied in short sequences, differing from each other by drug rotation. I. First of two parts: a phase I trial equivalent, concerning five virostatics: AZT, ddI, ddC, acriflavine and an ellipticine analogue.
    Mathé G, Pontiggia P, Orbach-Arbouys S, Triana K, Ambetima N, Morette C, Hallard M, Blanquet D.
    Biomed Pharmacother; 1996 Feb 30; 50(5):220-7. PubMed ID: 8949403
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.